Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 6 | Molecular Cancer

Figure 6

From: Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer

Figure 6

Competition of Bright-complemented in vitro transcription by a high affinity Bright-binding P2 site. Prior to NTP initiation of in vitro transcription on the Eμ+MARs template, either no oligonucleotide (lanes 1,2), or increasing concentrations of a duplexed wild-type P2 oligo (lanes 5,6) or a duplexed mutant (mut) P2 oligo (substituted in 5 core positions to eliminate Bright binding) (lanes 7,8) were added to the reaction prior to chromatin assembly (Step 1 conditions). In vitro generated transcripts were measured by RNase protection and compared to total RNA isolated from BCL1 leukemia cells (~0.5 μg; lane 9).

Back to article page